These nanoparticle–aptamer drug conjugates have effectively delivered cisplatin to PSMA-positive prostate cancer, with the cytotoxic drugs docetaxel and paclitaxel embedded in biodegradable polymers [175] or cisplatin precursors containing Pt(IV). This evidence concerns the gene FOLH1 and prostate carcinoma.